

COLUMBA: Long-term safety and durability of mepolizumab response in patients with severe eosinophilic asthma

Study design and treatment

Open label

Single arm

Multi-center

Extension study



Mepolizumab
100 mg SC
every 4 weeks




Patients treated
for up to
4.5 years



347 patients
treated


Exacerbation rates per year across DREAM* and COLUMBA†



*Dose Ranging Efficacy And safety with Mepolizumab in severe asthma trial

†Based on 286 patients with ≥156 weeks of open-label data in COLUMBA

On-treatment AEs occurring in >10% of patients during COLUMBA



Overall, no new safety concerns were identified with long-term treatment (1201 patient years)